Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.43
Price to sales ratio

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
4441
ATNM
Actinium Pharmaceuticals, Inc. Common Stock
1.01 USD-0.98%-5.61%+20.24%-2.88%31.76 M USD
4445
ESLA
Estrella Immunopharma, Inc. - Common Stock
0.71 USD-1.39%-6.58%-6.58%-33.02%30.88 M USD
4470
GRDX
GridAI Technologies Corp. - Common Stock
3.96 USD-1.25%+17.16%+54.69%+55.29%28.24 M USD
4473
NXTC
NextCure, Inc. - Common Stock
6.09 USD+0.83%+2.87%+22.29%-53.51%27.88 M USD

Frequently asked questions about Barinthus Biotherapeutics plc American Depositary Shares

What is the Barinthus Biotherapeutics plc American Depositary Shares stock price today?

The current price of Barinthus Biotherapeutics plc American Depositary Shares (BRNS) is 0.75. Over the past 24 hours, the stock has changed by 0.00%. Follow the BRNS chart for real-time price dynamics.

What is the stock ticker of Barinthus Biotherapeutics plc American Depositary Shares?

Barinthus Biotherapeutics plc American Depositary Shares trades under the ticker BRNS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Barinthus Biotherapeutics plc American Depositary Shares stock going up?

BRNS has changed by +19.05% over the last week, +36.36% over the last month, and -39.02% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Barinthus Biotherapeutics plc American Depositary Shares?

Barinthus Biotherapeutics plc American Depositary Shares currently has a market capitalization of 30.64 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Barinthus Biotherapeutics plc American Depositary Shares earnings last quarter?

Last quarter, Barinthus Biotherapeutics plc American Depositary Shares reported earnings of -0.26 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Barinthus Biotherapeutics plc American Depositary Shares revenue for the last quarter?

Barinthus Biotherapeutics plc American Depositary Shares reported quarterly revenue of 5 000. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Barinthus Biotherapeutics plc American Depositary Shares net income for the last quarter?

Barinthus Biotherapeutics plc American Depositary Shares reported net income of -10.58 M for the last quarter. The previous quarter showed -5.53 M, which means net income changed by -91.29%.

How many employees does Barinthus Biotherapeutics plc American Depositary Shares have?

As of the latest available data, Barinthus Biotherapeutics plc American Depositary Shares has 14 employees. Workforce size can provide additional context about the company's scale and operations.

What is Barinthus Biotherapeutics plc American Depositary Shares EBITDA?

Barinthus Biotherapeutics plc American Depositary Shares EBITDA is -10.2 M, and its EBITDA margin is -203.98 K%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Barinthus Biotherapeutics plc American Depositary Shares stock?

You can buy Barinthus Biotherapeutics plc American Depositary Shares (BRNS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Barinthus Biotherapeutics plc American Depositary Shares stock?

Investing in Barinthus Biotherapeutics plc American Depositary Shares requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the BRNS chart and related analysis on metatrader.com as part of your research.

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.

News